Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment
Open accessThe DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.
Abstract
Pemafibrate (K-877) is a novel selective peroxisome proliferator-activated receptor-α modulator (SPPARMα) with a favorable benefit-risk balance. Previous clinical trials of pemafibrate used stringent exclusion criteria related to renal functions. Therefore, we investigated its safety and efficacy in a broader range of patients, including those with chronic kidney disease (CKD). In this multicenter, single-arm, open-label, phase III trial, 0.2–0.4 mg/day pemafibrate was administered for 52 weeks to 189 patients with hypertriglyceridemia and an estimated glomerular filtration rate (eGFR) ≥ 45 mL/min/1.73 m2 on statin or regardless of eGFR when statin was not administered. Post-hoc analyses were performed on subgroups stratified by baseline eGFR. Triglyceride levels decreased by 45.9% at week 52 (last-observation-carried-forward). These reductions were not correlated with baseline eGFR. The eGFR < 30 mL/min/1.73 m2 subgroup showed the greatest reduction in chylomicron, very low-density lipoprotein, small low-density lipoprotein cholesterol levels, and an increase in high-density lipoprotein cholesterol levels. The incidences of adverse events and adverse drug reactions were 82.0% and 31.7%, respectively, and these were not associated with baseline eGFR. In CKD patients, pemafibrate blood concentrations were not elevated. Pemafibrate showed a good safety profile and efficacy in correcting lipid abnormalities in a broad range of patients, including those with CKD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“No major increase in blood pemafibrate concentrations was observed even after administering repeated dosage [94].”
From Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases (2020) · cites this paper as [94]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
Differential Diagnosis of Glomerular Disease: A Systematic and Inclusive Approach
Hebert, L. A., Parikh, S., Prosek, J., Nadasdy, T., & Rovin, B. H. (2013) · American Journal of Nephrology · doi:10.1159/000354390 · Cited by 4,376
(2010) · The Lancet · doi:10.1016/s0140-6736(10)60674-5 · Cited by 4,200 · cited 1×
“Reduced renal function is associated with elevated risks of cardiovascular disease (CVD) and death [5,6].”
BackgroundMortality by cause for eight regions of the world: Global Burden of Disease Study
Murray, C. J., & Lopez, A. D. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07493-4 · Cited by 4,043 · cited 1×
“Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of death [1,2].”
Background2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Andrassy, K. M. (2013) · Kidney International · doi:10.1038/ki.2013.243 · Cited by 2,496
Levey, A. S., de Jong, P. E., Coresh, J., El Nahas, M., Astor, B. C., Matsushita, K., Gansevoort, R. T., Kasiske, B. L., & Eckardt, K.-U. (2011) · Kidney International · doi:10.1038/ki.2010.483 · Cited by 2,345 · cited 1×
“Reduced renal function is associated with elevated risks of cardiovascular disease (CVD) and death [5,6].”
Background2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs
Graham, D. J. (2004) · JAMA · doi:10.1001/jama.292.21.2585 · Cited by 875 · cited 2×
“Therefore, the concomitant use of these drugs should be avoided in these patients, whereas the risks vary with different fibrates and statins used in combination [20].”
BackgroundDrug Treatment of Lipid Disorders
Knopp, R. H. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908123410707 · Cited by 845 · cited 1×
“Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of death [1,2].”
BackgroundDyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences
Vaziri, N. D. (2006) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00099.2005 · Cited by 538 · cited 2×
“Atherogenic dyslipidemia, characterized by increased TG-rich lipoproteins and decreased HDL-C levels, is frequently observed in patients with reduced renal function, which itself is associated with CVD risk [7].”
BackgroundSafety considerations with fibrate therapy
Davidson, M. H., Armani, A., McKenney, J. M., & Jacobson, T. A. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.016 · Cited by 408 · cited 8×
“In the present phase III trial, a broad range of patients—including those with impaired renal function (CKD stages G3a, G3b, G4, an G5, and receiving hemodialysis)— as recruit , a d the duration of administration (52 weeks) was longer than that in previous p mafibrate trials.”
BackgroundInfluentialSummary of Recommendation Statements
(2013) · Kidney International Supplements · doi:10.1038/kisup.2012.77 · Cited by 396
Fruchart, J.-C., Sacks, F. M., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.046 · Cited by 260 · cited 1×
“Residual lipid abnormalities, such as elevated triglyceride (TG) and/or reduced high-density lipoprotein (HDL)-cholesterol (HDL-C) levels, are secondary targets [3,4].”
BackgroundNiacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk
Chapman, M. J., Redfern, J. S., McGovern, M. E., & Giral, P. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.01.008 · Cited by 227 · cited 1×
“Residual lipid abnormalities, such as elevated triglyceride (TG) and/or reduced high-density lipoprotein (HDL)-cholesterol (HDL-C) levels, are secondary targets [3,4].”
BackgroundIshibashi, S., Yamashita, S., Arai, H., Araki, E., Yokote, K., Suganami, H., Fruchart, J.-C., & Kodama, T. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.02.029 · Cited by 208 · cited 2×
“Compared to other PPARα agonists, pemafibrate does not significantly increase, and may even decrease, alanine aminotransferase (ALT) or γ-glutamyltransferase (γ-GT) levels [22,24,26].”
BackgroundResultSelf-citationFruchart, J.-C. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-82 · Cited by 189
Ishibashi, S., Arai, H., Yokote, K., Araki, E., Suganami, H., & Yamashita, S. (2018) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2017.10.006 · Cited by 184
Self-citationDyslipidemia Associated with Chronic Kidney Disease
Tsimihodimos, V., Mitrogianni, Z., & Elisaf, M. (2011) · The Open Cardiovascular Medicine Journal · doi:10.2174/1874192401105010041 · Cited by 174
Araki, E., Yamashita, S., Arai, H., Yokote, K., Satoh, J., Inoguchi, T., Nakamura, J., Maegawa, H., Yoshioka, N., Tanizawa, Y., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1589 · Cited by 164 · cited 1×
“The AE and ADR incidences and profiles in patients administered pemafibrate alone or in combination with a statin were comparable to those observed in the placebo group [22,23,25,26].”
ResultSelf-citationFibrate‐induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?
Broeders, N., Knoop, C., Antoine, M., Tielemans, C., & Abramowicz, D. (2000) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/15.12.1993 · Cited by 163
Reiss, A. B., Voloshyna, I., Leon, J. D., Miyawaki, N., & Mattana, J. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.06.028 · Cited by 147
Fruchart, J.-C. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0602-y · Cited by 141
Arai, H., Yamashita, S., Yokote, K., Araki, E., Suganami, H., Ishibashi, S., & on behalf of the K-877 Study Group (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.44412 · Cited by 136 · cited 3×
“According to an earlier report, hypertriglyceridemic patients with normal renal function receiving pemafibrate treatment had lower incidences of AEs and ADRs than those receiving fenofibrate [24,26].”
BackgroundResultSelf-citationArai, H., Yamashita, S., Yokote, K., Araki, E., Suganami, H., & Ishibashi, S. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.03.032 · Cited by 124 · cited 1×
“The AE and ADR incidences and profiles in patients administered pemafibrate alone or in combination with a statin were comparable to those observed in the placebo group [22,23,25,26].”
ResultSelf-citationDeterioration in renal function associated with fibrate therapy.
Lipscombe, J., Lewis, G. F., Cattran, D. C., & Bargman, J. M. (2001) · PubMed · Cited by 111
Yamazaki, Y., Abe, K., Toma, T., Nishikawa, M., Ozawa, H., Okuda, A., Araki, T., Oda, S., Inoue, K., Shibuya, K., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.05.066 · Cited by 84
Remick, J., Weintraub, H., Setton, R., Offenbacher, J., Fisher, E., & Schwartzbard, A. (2008) · Cardiology in Review · doi:10.1097/crd.0b013e31816b43d3 · Cited by 83
Fenofibrate and the kidney: an overview
Kostapanos, M. S., Florentin, M., & Elisaf, M. S. (2013) · European Journal of Clinical Investigation · doi:10.1111/eci.12068 · Cited by 65
Management of Dyslipidemias in Patients with Diabetes and Chronic Kidney Disease
Molitch, M. E. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00780306 · Cited by 63
Fenofibrate-associated nephrotoxicity: A review of current evidence
Attridge, R. L., Frei, C. R., Ryan, L., Koeller, J., & Linn, W. D. (2013) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp120131 · Cited by 57
Pemafibrate: First Global Approval
Blair, H. A. (2017) · Drugs · doi:10.1007/s40265-017-0818-x · Cited by 54 · cited 2×
“Moreover, a pharmacokinetic study of a single oral administration of pemafibrate in patients with normal and impaired renal function showed no increase in systemic exposure in a renal function-dependent manner [27,31].”
BackgroundFibrates in the management of atherogenic dyslipidemia
Okopień, B., Bułdak, Ł., & Bołdys, A. (2017) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2017.1408410 · Cited by 53 · cited 1×
“Although atherogenic dyslipidemia can be ameliorated with peroxisome proliferator-activated receptor α (PPARα) agonists [8], clinical trials have shown that these agents increase serum creatinine levels [9–14].”
BackgroundMottl, A. K., Buse, J. B., Ismail-Beigi, F., Sigal, R. J., Pedley, C. F., Papademetriou, V., Simmons, D. L., Katz, L., Mychaleckyj, J. C., & Craven, T. E. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06200518 · Cited by 48
Honda, H., Hirano, T., Ueda, M., Kojima, S., Mashiba, S., Hayase, Y., Michihata, T., & Shibata, T. (2015) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.30015 · Cited by 42 · cited 1×
“In addition, apoA1 and apoA2 levels are decreased in these patients [36].”
BackgroundFenofibrate‐Induced Elevation in Serum Creatinine
Ritter, J. L., & Nabulsi, S. (2001) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.21.13.1145.34623 · Cited by 39
Furusyo, N., Ai, M., Okazaki, M., Ikezaki, H., Ihara, T., Hayashi, T., Hiramine, S., Ura, K., Kohzuma, T., Schaefer, E. J., et al. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.09.008 · Cited by 32 · cited 6×
“* p < 0.05, ** p < 0.01, *** p < 0.001 vs. baseline by one sample t-test. eGFR, estimated glomerular filtration rate; CM-C, chylomicron cholesterol; VLDL-C, very-low-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; HPLC, high-performance liquid c…”
MethodInfluentialEffect of Hemodialysis on Plasma Kinetics of Fenofibrate in Chronic Renal Failure
Desager, J. P., Costermans, J., Verberckmoes, R., & Harvengt, C. (2008) · The Nephron journals/Nephron journals · doi:10.1159/000182614 · Cited by 28
The short term effects of bezafibrate on the hypertriglyceridaemia of moderate to severe uraemia.
Williams, A., Baker, F., & Walls, J. (1984) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1984.tb02477.x · Cited by 26
Elevated serum creatinine levels associated with fenofibrate therapy
McQuade, C. R., Griego, J. E., Anderson, J. E., & Pai, A. B. (2008) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp070005 · Cited by 25
Pharmacokinetics of bezafibrate after single and multiple doses in the presence of renal failure
Abshagen, U., K�sters, W., Kaufmann, B., & Lang, P. D. (1980) · Journal of Molecular Medicine · doi:10.1007/bf01477001 · Cited by 23
Makówka, A., Dryja, P., Chwatko, G., Bald, E., & Nowicki, M. P. (2012) · Lipids in Health and Disease · doi:10.1186/1476-511x-11-47 · Cited by 18
Pemafibrate Has High Bioavailability and is Principally Excreted via the Liver
Hounslow, N., Mair, S., Suganami, H., & Nakamura, M. (2018) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2018.04.475 · Cited by 16 · cited 1×
“Moreover, unlike many other PPARα agonists, pemafibrate is principally excreted via the liver [15,27,30] and exposure to pemafibrate is not dependent on the severity of renal dysfunction [27,31].”
BackgroundSelf-citationClinical pharmacokinetics of bezafibrate in patients with impaired renal function
Anderson, P., & Norbeck, H. (1981) · European Journal of Clinical Pharmacology · doi:10.1007/bf00627922 · Cited by 15
AbdelMagid, A. M., Abbassi, M., Iskander, E. E. M., Mohamady, O., & Farid, S. F. (2017) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2016-0076 · Cited by 11
Lipid-Lowering Therapy in CKD: Should We Use It and in Which Patients
Kaysen, G. A. (2017) · Blood Purification · doi:10.1159/000452727 · Cited by 8
Liang, C., Wang, I., Kuo, H., Yeh, H., Lin, H., Liu, Y., Hsu, W.-M., Huang, C., & Chang, C. (2011) · Renal Failure · doi:10.3109/0886022x.2011.577545 · Cited by 7
Hosford, D., Gordon, G., Suganami, H., & Nakamura, M. (2018) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2018.04.458 · Cited by 6 · cited 2×
“Moreover, a pharmacokinetic study of a single oral administration of pemafibrate in patients with normal and impaired renal function showed no increase in systemic exposure in a renal function-dependent manner [27,31].”
BackgroundSelf-citation
Cited by
Okamura, T., Tsukamoto, K., Arai, H., Fujioka, Y., Ishigaki, Y., Koba, S., Ohmura, H., Shoji, T., Yokote, K., Yoshida, H., et al. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2022 · Cited by 302
Self-citationNonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors
Francque, S., Szabo, G., Abdelmalek, M. F., Byrne, C. D., Cusi, K., Dufour, J.-F., Roden, M., Sacks, F., & Tacke, F. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00366-5 · Cited by 316
Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence
Cheng, H. S., Tan, W. R., Low, Z. S., Marvalim, C., Lee, J. Y. H., & Tan, N. S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205055 · Cited by 264
PPARs as Nuclear Receptors for Nutrient and Energy Metabolism
Hong, F., Pan, S., Guo, Y., Xu, P., & Zhai, Y. (2019) · Molecules · doi:10.3390/molecules24142545 · Cited by 233
Yamashita, S., Masuda, D., & Matsuzawa, Y. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-0823-5 · Cited by 191
Self-citation
Metadata
- Authors
- Yokote, K., Yamashita, S., Arai, H., Araki, E., Suganami, H., & Ishibashi, S.
- Affiliations
- Chiba University (JP)
- Rinku General Medical Center (JP)
- National Center for Geriatrics and Gerontology (JP)
- Kumamoto University (JP)
- Kowa (Japan) (JP)
- Jichi Medical University (JP)
- Corresponding author
- Yokote, Koutaro
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-02-06
- Volume
- 20
- Issue
- 3
- Pages
- 706
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC6386904
- OpenAlex
- W2913672551
- Cited by
- 79
- References
- 48
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 12 · 2023: 14 · 2022: 9 · 2021: 12 · 2020: 10 · 2019: 9
- FWCI
- 3.31
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Kowa Company
- Japan Society for the Promotion of Science (17K19643, 17H04201, 17H02100, 18K08482)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- pemafibrate, PPARα modulator, chronic kidney disease, renal dysfunction, hypertriglyceridemia, dyslipidemia, triglyceride lowering, lipid-lowering therapy, drug safety, adverse drug reactions
- MeSH terms
- Aged, Benzoxazoles, Butyrates, Female, Humans, Kidney Function Tests, Lipids, Male, Middle Aged, Biomarkers, Treatment Outcome, PPAR alpha, Dyslipidemias, Renal Insufficiency
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.